Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13619906 | 0.84 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1MEN1CRHBPKMT2A | |
| SCHEMBL13619916 | 0.80 | MMP1 (0.38) | MEN1KMT2AMAPT | |
| SCHEMBL7782935 | 0.79 | ALDH1A1 (0.47) | L3MBTL1ALDH1A1MEN1CRHBPKMT2A | |
| SCHEMBL27571004 | 0.78 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1MEN1CRHBPKMT2A | |
| SCHEMBL16727251 | 0.76 | MAPT (0.39) | L3MBTL1ALDH1A1MEN1CRHBPKMT2A | |
| SCHEMBL13619907 | 0.73 | MAPT (0.50) | L3MBTL1ALDH1A1MEN1CRHBPKMT2A | |
| SCHEMBL11648038 | 0.72 | ALDH1A1 (0.41) | ALDH1A1MAPT | |
| SCHEMBL8373359 | 0.72 | ALDH1A1 (0.41) | ALDH1A1MAPT | |
| SCHEMBL8371983 | 0.72 | ALDH1A1 (0.41) | ALDH1A1MAPT | |
| SCHEMBL13619914 | 0.72 | ALDH1A1 (0.44) | L3MBTL1ALDH1A1MEN1CRHBPKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281067-A1 | Nitroxyl progenitor compounds and methods of use | THE JOHN HOPKINS UNIVERSITY (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281067-A1 | Nitroxyl progenitor compounds and methods of use | THE JOHN HOPKINS UNIVERSITY (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281067-A1 | Nitroxyl progenitor compounds and methods of use | HMOX2, NNMT, HMOX1 | L3MBTL1 889/4885ALDH1A1 37/4885MEN1 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.